WO2020204644A1 - Composition containing healthy extract as active ingredient for enhancing production rates of neutralizing antibodies - Google Patents

Composition containing healthy extract as active ingredient for enhancing production rates of neutralizing antibodies Download PDF

Info

Publication number
WO2020204644A1
WO2020204644A1 PCT/KR2020/004542 KR2020004542W WO2020204644A1 WO 2020204644 A1 WO2020204644 A1 WO 2020204644A1 KR 2020004542 W KR2020004542 W KR 2020004542W WO 2020204644 A1 WO2020204644 A1 WO 2020204644A1
Authority
WO
WIPO (PCT)
Prior art keywords
extract
neutralizing antibodies
health
enhancing
production rate
Prior art date
Application number
PCT/KR2020/004542
Other languages
French (fr)
Korean (ko)
Inventor
유수성
이호영
김지현
심은형
Original Assignee
한국 한의학 연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국 한의학 연구원 filed Critical 한국 한의학 연구원
Publication of WO2020204644A1 publication Critical patent/WO2020204644A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9068—Zingiber, e.g. garden ginger
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution

Definitions

  • the present invention relates to a composition for enhancing the production rate of neutralizing antibodies comprising a health extract as an active ingredient.
  • the flu virus occurs worldwide every year and causes respiratory disease, which has a high mortality rate in children and the elderly with weak immune systems, and complications include bronchial diseases such as pneumonia and cardiopulmonary disease. If it does, the mortality rate is even higher, which can be said to have a great impact on the public health.
  • the pandemic flu virus which occurs every 10 to 20 years, is very deadly, such as the Spanish flu virus, which killed about 20 million people in 1918. It is said that this flu virus has not occurred since the Hong Kong flu virus of the 60s. Considering that, the emergence of a deadly flu virus is expected in the near future.
  • the World Health Organization WHO
  • WHO World Health Organization
  • Antibody formation is expected to be well-formed in most healthy people, but it is known that antibody formation is very low in patients with low immunity or in the elderly.
  • the present invention is derived from the above requirements, the present invention provides a composition for enhancing the production rate of neutralizing antibodies comprising a health extract as an active ingredient, and after administering the health extract, which is an active ingredient of the present invention, vaccination
  • a composition for enhancing the production rate of neutralizing antibodies comprising a health extract as an active ingredient, and after administering the health extract, which is an active ingredient of the present invention, vaccination
  • One animal model showed that the formation of antigen-specific antibodies was enhanced, the rate of cytokine produced by antigen stimulation, which was lowered by anticancer drugs, was restored, and the rate of antibody production against H1N1 and H3N2 antigens after vaccination was enhanced. By confirming this, the present invention was completed.
  • the present invention provides a health functional food composition for enhancing the production rate of neutralizing antibodies formed by flu vaccination comprising a health extract as an active ingredient.
  • the present invention provides a pharmaceutical composition for enhancing the production rate of neutralizing antibodies formed by flu vaccination comprising a health extract as an active ingredient.
  • the present invention provides a flu vaccine adjuvant for enhancing the production rate of neutralizing antibodies comprising a health extract as an active ingredient.
  • the present invention relates to a composition for enhancing the production rate of neutralizing antibodies comprising a healthy extract as an active ingredient, and after administering the healthy extract of the present invention, in the animal model inoculated with the vaccine, the formation of antigen-specific antibodies was enhanced, and decreased by anticancer agents.
  • the rate of production of cytokines generated by antigen stimulation is restored, and after vaccination, the rate of antibody production against H1N1 and H3N2 antigens is increased.
  • the present invention relates to a health functional food composition for enhancing the production rate of neutralizing antibodies formed by flu vaccination comprising a health extract as an active ingredient.
  • the health extract may be prepared by a method comprising the following steps, but is not limited thereto:
  • step (3) preparing an extract by concentrating the filtered extract in step (2) under reduced pressure and drying it.
  • the extraction solvent is preferably selected from water, a lower alcohol of C 1 to C 4 or a mixture thereof, more preferably ethanol and even more preferably 70% (v/v) ethanol, but Not limited.
  • the extraction solvent is preferably extracted by adding 1 to 20 times the weight of the dried healthy, more preferably 5 to 15 times.
  • the extraction temperature is preferably 4 to 110 °C, more preferably 82 ⁇ 2 °C, but is not limited thereto.
  • the extraction time is preferably 0.5 to 10 hours, more preferably 0.5 to 5 hours, but is not limited thereto.
  • the vacuum concentration in step (3) is preferably a vacuum vacuum concentrator or a vacuum rotary evaporator, but is not limited thereto.
  • the drying is preferably vacuum drying, vacuum drying, boiling drying, spray drying, or freeze drying, but is not limited thereto.
  • the neutralizing antibody is preferably an antibody against H1N1 or H3N2 type A flu virus infection, or an antibody against B/Phuket or B/Bristone type B flu virus infection, but is not limited thereto.
  • the composition is preferably administered to a cancer patient with reduced immunity or an elderly person aged 60 years or older prior to inoculation of the flu vaccine, but is not limited thereto.
  • the administration is preferably administered 1 month to 10 days before vaccination, but is not limited thereto.
  • Administration is preferably oral administration, but is not limited thereto.
  • the health functional food composition is preferably prepared in any one formulation selected from powders, granules, pills, tablets, capsules, candy, syrup, and beverages, but is not limited thereto, and may be prepared by adding it as an ingredient of food, and conventional It can be suitably manufactured according to the phosphorus method.
  • foods to which the health extract of the present invention can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, It may be in any one form selected from tea, drink, alcoholic beverage, and vitamin complex, and includes all health functional foods in the usual sense.
  • the health functional food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective properties. It may contain colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, it may contain pulp for the manufacture of natural fruit juices and vegetable beverages. These components may be used independently or in combination.
  • the health functional food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients.
  • the natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol.
  • sweetener natural sweeteners such as taumatin and stevia extract, and synthetic sweeteners such as saccharin and aspartame can be used.
  • the present invention relates to a pharmaceutical composition for enhancing the production rate of neutralizing antibodies formed by flu vaccination comprising a health extract as an active ingredient.
  • the pharmaceutical composition of the present invention may further include a carrier, excipient, or diluent in addition to the health extract, and the pharmaceutical composition of the present invention may be administered orally or parenterally.
  • the pharmaceutical composition may be administered externally to the skin or intraperitoneally, or , It is preferable to select intravenous, intramuscular, subcutaneous, intrauterine dura mater or cerebrovascular injection.
  • the pharmaceutical composition of the present invention may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants.
  • Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient in one or more compounds, such as starch, calcium carbonate, sucrose, or lactose ( lactose), gelatin, etc.
  • lubricants such as magnesium stearate and talc are also used.
  • Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, syrups, etc.In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweetening agents, fragrances, and preservatives may be included. have.
  • Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories.
  • the non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used.
  • As a base for suppositories witepsol, macrogol, tween 61, cacao butter, laurin, glycero gelatin, and the like may be used.
  • the composition according to the present invention is administered in a pharmaceutically effective amount.
  • the'pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type of disease, severity, and drug activity of the patient. , Sensitivity to drugs, time of administration, route of administration and rate of excretion, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field.
  • the composition of the present invention may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, may be administered sequentially or simultaneously with a conventional therapeutic agent, and may be administered single or multiple. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and this can be easily determined by a person skilled in the art.
  • the dosage of the composition of the present invention can be used in various ranges according to the patient's weight, age, sex, health status, diet, administration time, administration method, excretion rate, and severity of disease.
  • the present invention relates to a flu vaccine adjuvant for enhancing the production rate of neutralizing antibodies comprising a health extract as an active ingredient.
  • the flu vaccine adjuvant may contain one or more active ingredients exhibiting the same or similar function in addition to the health extract.
  • the flu vaccine adjuvant can be administered orally or parenterally during clinical administration, and when administered parenterally, intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, intrauterine dural injection, cerebrovascular injection or It can be administered by intrathoracic injection, and can be used in the form of a general pharmaceutical formulation.
  • the flu vaccine adjuvant of the present invention can be administered in various parenteral formulations at the time of actual clinical administration, but when formulated, diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants are used. It is prepared by doing. Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like may be used.
  • Reflux extraction was performed at 82 ⁇ 2° C. for 3 hours by adding 70% (v/v) ethanol 10 times the healthy weight. Then, after the sieve filter, the cotton filter was performed. The filtered solution was lyophilized to powder.
  • a Balb/c 8-week-old female mouse was purchased from Orient Bio, and the cyclophosphamide (Sigma) 150mg/kg was injected intraperitoneally three times at intervals of 2 days.
  • the experimental group was orally administered 500mg/kg of healthy extract for 10 days from the 3rd day after the last anticancer drug administration, and the control group was orally administered distilled water.
  • a flu vaccine of 1 ⁇ g of each influenza antibody was injected intramuscularly.
  • serum and splenocytes were isolated through autopsy.
  • the vaccine is a 2017-2018 seasonal vaccine, including A/Michigan/45/2015(H1N1), A/Hong Kong/4801/2014(H3N2), B/Phuket/3073/2013, B/Brisbane/60/2008 Is to do.
  • a total of 4 ⁇ g/ml of antigen per well was coated on a 96-well plate and blocked so that each influenza antigen was loaded at 1 ⁇ g/ml, and then, the mouse serum was diluted 10,000 times and incubated.
  • Anti-IgG antibody with HRP, anti-IgG1 antibody, and anti-IgG2a antibody was used to measure the titer of the influenza antigen-specific antibody by enzyme-linked immunosorbent assay (ELISA).
  • stimulation was divided into an anti-mouse CD28 Ab (1 ⁇ g/ml, biolegend) stimulation group and an anti-mouse CD28 Ab + influenza antigen (0.5 ⁇ g/mL) stimulation group in each well. Then, after 2 days of culture, the supernatant of the culture solution was separated. The production values of each cytokine were determined in the culture medium. Specifically, changes in the content of the cytokine IFN- ⁇ for T H 1 reaction evaluation and the cytokine IL-4 for T H 2 reaction evaluation were confirmed.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Nutrition Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention pertains to a composition for enhancing the production rates of neutralizing antibodies, the composition containing a healthy extract as an active ingredient. In an animal model inoculated with a vaccine after the administration of the healthy extract of the present invention, there are the effects in which the formation of antigen-specific antibodies is enhanced, the production rate of cytokine produced by antigen stimulation, which has been lowered by anticancer drugs, is restored, and the production rates of antibodies to H1N1 and H3N2 antigens are enhanced after vaccination. Thus, applying the composition of the present invention to immunocompromised patients or the elderly prior to flu vaccination is expected to increase the production rate of antibodies.

Description

건강 추출물을 유효성분으로 포함하는 중화항체 생성율 증진용 조성물Composition for enhancing the production rate of neutralizing antibodies comprising healthy extracts as active ingredients
본 발명은 건강 추출물을 유효성분으로 포함하는 중화항체 생성율 증진용 조성물에 관한 것이다.The present invention relates to a composition for enhancing the production rate of neutralizing antibodies comprising a health extract as an active ingredient.
독감 바이러스는 매년 전세계적으로 발생하여 호흡기 질환을 일으키는데, 이 질환은 면역 능력이 약한 어린이와 노인들에 대해 치사율이 높고, 합병증으로 폐렴(pneumonia), 심폐질환(cardiopulmonary disease) 등의 기관지 질환들을 수반하는 경우 치사율이 더욱 높아져 국민 보건에 미치는 영향이 크다고 할 수 있다. The flu virus occurs worldwide every year and causes respiratory disease, which has a high mortality rate in children and the elderly with weak immune systems, and complications include bronchial diseases such as pneumonia and cardiopulmonary disease. If it does, the mortality rate is even higher, which can be said to have a great impact on the public health.
특히 1918년에 약 2,000 만명의 사망자를 낸 스페인 독감 바이러스와 같이, 10 내지 20년 주기로 전세계으로 출현하는(pandemic) 독감 바이러스는 매우 치명적인데, 60년대의 홍콩 독감 바이러스 이후 이러한 독감 바이러스가 발생하지 않았다는 점을 고려하면, 가까운 미래에 치명적인 독감 바이러스의 출현이 예상되고 있다. 이러한 독감 바이러스의 예방을 위해, 세계 보건 기구(WHO)는 통계를 토대로 1 년후에 발생가능한 독감 바이러스를 세 유형별로 미리 선정하여 고시함으로써 백신이 보급되도록 하고 있다. 하지만 아직까지 백신을 접종한 후, 항체 형성 여부에 대한 검증은 이루어지지 않고 있다. 대부분의 건강한 사람은 항체 형성이 잘 이루졌을 것으로 예상되지만 면역력이 낮아진 환자군 또는 노인들의 경우는 항체 형성이 매우 낮은 것으로 알려져 있다. In particular, the pandemic flu virus, which occurs every 10 to 20 years, is very deadly, such as the Spanish flu virus, which killed about 20 million people in 1918. It is said that this flu virus has not occurred since the Hong Kong flu virus of the 60s. Considering that, the emergence of a deadly flu virus is expected in the near future. In order to prevent such flu virus, the World Health Organization (WHO) is pre-selecting and notifying the three types of flu viruses that can occur after one year based on statistics so that the vaccine is distributed. However, after vaccination, there is still no verification of the formation of antibodies. Antibody formation is expected to be well-formed in most healthy people, but it is known that antibody formation is very low in patients with low immunity or in the elderly.
이와 같이 바이러스 감염에 취약한 환자 또는 노인이 예방접종을 통해 항체 생성률이 낮다는 문제점이 제기되고 있으나, 아직까지는 이를 극복하기 위한 방안 마련은 거의 없는 수준이다. As such, a problem has been raised that patients or the elderly who are susceptible to viral infection have a low antibody production rate through vaccination, but there are few measures to overcome this problem.
한편, 건강( Zingiber officinale)은 아열대 및 열대성 다년생 식물로서 근경을 주로 식용하며, 그 특유한 향기와 매운 맛으로 인하여 오랫동안 향신료로서 사용되고 있다. 생강의 생리 활성 성분이 항균작용, 항염작용, 혈청 콜레스테롤 저하 효과, 항산화 작용을 나타내는 것으로 알려져 있다. 건강으로부터 분리한 올레오레진(oleoresin), 진저롤(gingerol) 및 쇼가올(shogaol)이 자연살해세포 기능을 활성화시켜 면역능 증진에 효과가 있다는 것으로 알려져 있고, [한국영양과학회지 37(1); 23~30, 2004]에 생강추출물 투여가 마우스 면역세포 활성에 미치는 영향이 개시되어 있으며, 한국등록특허 제1324926호에 생강 추출물 제조방법 및 이에 따른 생강 추출물이 개시되어 있으나, 본 발명의 건강 추출물을 유효성분으로 포함하는 중화항체 생성율 증진용 조성물에 대해 개시된 바는 없다. On the other hand, health ( Zingiber officinale ) is a subtropical and tropical perennial plant, mainly edible rhizomes, and has been used as a spice for a long time due to its peculiar aroma and spicy taste. It is known that the physiologically active ingredients of ginger have antibacterial, anti-inflammatory, serum cholesterol lowering, and antioxidant effects. It is known that oleoresin, gingerol, and shogaol isolated from health are effective in enhancing immunity by activating natural killer cell functions, [Journal of the Korean Society of Nutrition 37(1); 23-30, 2004] discloses the effect of administration of ginger extract on the activity of mouse immune cells, and Korean Patent No. 1324926 discloses a method for preparing a ginger extract and a ginger extract according thereto, but the health extract of the present invention There is no disclosure about a composition for enhancing the production rate of neutralizing antibodies containing as an active ingredient.
본 발명은 상기와 같은 요구에 의해 도출된 것으로서, 본 발명은 건강 추출물을 유효성분으로 포함하는 중화항체 생성율 증진용 조성물을 제공하고, 본 발명의 유효성분인 건강 추출물을 투여한 후, 백신을 접종한 동물모델은 항원 특이 항체 형성이 증진되었고, 항암제에 의해 저하되었던 항원 자극에 의해 생성되는 사이토카인의 생성 비율이 회복되며, 백신 접종 후, H1N1 및 H3N2 항원에 대한 항체 생성율이 증진되는 효과가 있다는 것을 확인함으로써, 본 발명을 완성하였다.The present invention is derived from the above requirements, the present invention provides a composition for enhancing the production rate of neutralizing antibodies comprising a health extract as an active ingredient, and after administering the health extract, which is an active ingredient of the present invention, vaccination One animal model showed that the formation of antigen-specific antibodies was enhanced, the rate of cytokine produced by antigen stimulation, which was lowered by anticancer drugs, was restored, and the rate of antibody production against H1N1 and H3N2 antigens after vaccination was enhanced. By confirming this, the present invention was completed.
상기 목적을 달성하기 위하여, 본 발명은 건강 추출물을 유효성분으로 포함하는 독감 백신 접종에 의해 형성되는 중화항체 생성율 증진용 건강기능식품 조성물을 제공한다.In order to achieve the above object, the present invention provides a health functional food composition for enhancing the production rate of neutralizing antibodies formed by flu vaccination comprising a health extract as an active ingredient.
또한, 본 발명은 건강 추출물을 유효성분으로 포함하는 독감 백신 접종에 의해 형성되는 중화항체 생성율 증진용 약학 조성물을 제공한다.In addition, the present invention provides a pharmaceutical composition for enhancing the production rate of neutralizing antibodies formed by flu vaccination comprising a health extract as an active ingredient.
또한, 본 발명은 건강 추출물을 유효성분으로 포함하는 중화항체 생성율 증진용 독감 백신 보조제를 제공한다.In addition, the present invention provides a flu vaccine adjuvant for enhancing the production rate of neutralizing antibodies comprising a health extract as an active ingredient.
본 발명은 건강 추출물을 유효성분으로 포함하는 중화항체 생성율 증진용 조성물에 관한 것으로, 본 발명의 건강 추출물을 투여한 후, 백신을 접종한 동물모델은 항원 특이 항체 형성이 증진되었고, 항암제에 의해 저하되었던 항원 자극에 의해 생성되는 사이토카인의 생성 비율이 회복되며, 백신 접종 후, H1N1 및 H3N2 항원에 대한 항체 생성율이 증진되는 효과가 있다.The present invention relates to a composition for enhancing the production rate of neutralizing antibodies comprising a healthy extract as an active ingredient, and after administering the healthy extract of the present invention, in the animal model inoculated with the vaccine, the formation of antigen-specific antibodies was enhanced, and decreased by anticancer agents. The rate of production of cytokines generated by antigen stimulation is restored, and after vaccination, the rate of antibody production against H1N1 and H3N2 antigens is increased.
도 1은 본 발명의 건강 추출물의 투여에 의해 IgG 및 IgG1의 생성이 증진된 것을 확인한 결과이다. *은 항암제를 투여한 군에 비해 본 발명의 항암제 및 건강 추출물을 투여한 군에서의 IgG 및 IgG1의 생성이 통계적으로 유의미하게 증가하였다는 것으로 p<0.05이다.1 is a result of confirming that the production of IgG and IgG1 was enhanced by administration of the health extract of the present invention. * Indicates that the production of IgG and IgG1 in the group administered with the anticancer agent and health extract of the present invention was statistically significantly increased compared to the group administered with the anticancer agent, and p<0.05.
도 2는 in vitro 항원 자극에 대한 IFN-γ 및 IL-4의 함량 변화를 확인한 결과로, *은 아무것도 투여하지 않은 대조군에 비해 항암제 또는 항암제와 건강추출물을 투여한 군에서의 IFN-γ 및 IL-4의 함량이 통계적으로 유의미하게 감소하였다는 것으로, p<0.05이다.2 is a result of confirming the change in the content of IFN-γ and IL-4 upon in vitro antigen stimulation, where * is IFN-γ and IL in the group administered with anticancer or anticancer agent and health extract compared to the control group to which nothing was administered. It was found that the content of -4 was statistically significant, and p<0.05.
도 3은 in vitro 항원 자극에 대한 IFN-γ 및 IL-4의 비율 변화를 확인한 결과로, *은 항암제 투여군에 비해 항암제와 건강추출물을 투여한 군에서의 IFN-γ/IL-4의 비율이 통계적으로 유의미하게 증가하였다는 것으로, p<0.05이다.3 is a result of confirming the change in the ratio of IFN-γ and IL-4 to in vitro antigen stimulation, * indicates the ratio of IFN-γ/IL-4 in the group administered with the anticancer agent and the health extract compared to the group administered with the anticancer agent. It was a statistically significant increase, p<0.05.
도 4는 IFN-γ/IL-4의 비율과 IgG 생성량과의 관계를 확인한 결과이다.4 is a result of confirming the relationship between the ratio of IFN-γ/IL-4 and the amount of IgG produced.
본 발명은 건강 추출물을 유효성분으로 포함하는 독감 백신 접종에 의해 형성되는 중화항체 생성율 증진용 건강기능식품 조성물에 관한 것이다.The present invention relates to a health functional food composition for enhancing the production rate of neutralizing antibodies formed by flu vaccination comprising a health extract as an active ingredient.
상기 건강 추출물은 하기의 단계를 포함하는 방법에 의해 제조할 수 있으나, 이에 한정하지 않는다:The health extract may be prepared by a method comprising the following steps, but is not limited thereto:
(1) 건강에 추출용매를 가하여 추출하는 단계;(1) extracting by adding an extraction solvent to health;
(2) 단계 (1)의 추출물을 여과하는 단계; 및 (2) filtering the extract of step (1); And
(3) 단계 (2)의 여과한 추출물을 감압 농축하고 건조하여 추출물을 제조하는 단계. (3) preparing an extract by concentrating the filtered extract in step (2) under reduced pressure and drying it.
상기 단계 (1)에서 추출용매는 물, C 1~C 4의 저급 알코올 또는 이들의 혼합물 중에서 선택하는 것이 바람직하며, 더 바람직하게는 에탄올이고 더욱더 바람직하게는 70%(v/v) 에탄올지만 이에 한정하지 않는다.In the step (1), the extraction solvent is preferably selected from water, a lower alcohol of C 1 to C 4 or a mixture thereof, more preferably ethanol and even more preferably 70% (v/v) ethanol, but Not limited.
상기 제조방법에 있어서, 추출방법은 여과법, 열수 추출, 침지 추출, 환류 냉각 추출 및 초음파 추출 등의 당 업계에 공지된 모든 통상적인 방법을 이용할 수 있다. 상기 추출용매는 건조된 건강 중량의 1~20배 첨가하여 추출하는 것이 바람직하며, 더 바람직하게는 5~15배 첨가하는 것이다. 추출온도는 4 내지 110℃인 것이 바람직하며, 더 바람직하게는 82±2℃이지만, 이에 한정하지 않는다. 또한, 추출시간은 0.5~10시간인 것이 바람직하며, 0.5~5시간이 더욱 바람직하나 이에 한정하지 않는다. 상기 방법에 있어서, 단계 (3)의 감압농축은 진공 감압 농축기 또는 진공회전증발기를 이용하는 것이 바람직하나 이에 한정하지 않는다. 또한, 건조는 감압건조, 진공건조, 비등건조, 분무 건조 또는 동결 건조하는 것이 바람직하나 이에 한정하지 않는다.In the above manufacturing method, all conventional methods known in the art, such as filtration, hot water extraction, immersion extraction, reflux cooling extraction, and ultrasonic extraction, can be used as the extraction method. The extraction solvent is preferably extracted by adding 1 to 20 times the weight of the dried healthy, more preferably 5 to 15 times. The extraction temperature is preferably 4 to 110 ℃, more preferably 82 ± 2 ℃, but is not limited thereto. In addition, the extraction time is preferably 0.5 to 10 hours, more preferably 0.5 to 5 hours, but is not limited thereto. In the above method, the vacuum concentration in step (3) is preferably a vacuum vacuum concentrator or a vacuum rotary evaporator, but is not limited thereto. In addition, the drying is preferably vacuum drying, vacuum drying, boiling drying, spray drying, or freeze drying, but is not limited thereto.
상기 중화항체는 H1N1 또는 H3N2의 A형 독감바이러스 감염에 대한 항체 또는 B/Phuket 또는 B/Bristone의 B형 독감바이러스 감염에 대한 항체인 것이 바람직하지만 이에 한정하지 않는다. The neutralizing antibody is preferably an antibody against H1N1 or H3N2 type A flu virus infection, or an antibody against B/Phuket or B/Bristone type B flu virus infection, but is not limited thereto.
상기 조성물은 면역력이 저하된 암환자 또는 60세 이상의 노인에게 독감 백신 접종 전에 투여하기 위한 것임이 바람직하지만 이에 한정하는 것은 아니다. 상기 투여는 백신 접종 1개월 전 내지 10일 전에 투여하는 것이 바람직하지만 이에 한정하지 않는다. 투여는 경구투여가 바람직하지만 이에 제한하는 것은 아니다.The composition is preferably administered to a cancer patient with reduced immunity or an elderly person aged 60 years or older prior to inoculation of the flu vaccine, but is not limited thereto. The administration is preferably administered 1 month to 10 days before vaccination, but is not limited thereto. Administration is preferably oral administration, but is not limited thereto.
상기 건강기능식품 조성물은 분말, 과립, 환, 정제, 캡슐, 캔디, 시럽 및 음료 중에서 선택된 어느 하나의 제형으로 제조되는 것이 바람직하지만 이에 한정하지 않고, 식품의 성분으로 첨가하여 제조될 수 있으며, 통상적인 방법에 따라 적절하게 제조될 수 있다. 본 발명의 건강 추출물을 첨가할 수 있는 식품의 일례로는 육류, 소시지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 중에서 선택된 어느 하나의 형태일 수 있으며, 통상적인 의미에서의 건강기능식품을 모두 포함한다.The health functional food composition is preferably prepared in any one formulation selected from powders, granules, pills, tablets, capsules, candy, syrup, and beverages, but is not limited thereto, and may be prepared by adding it as an ingredient of food, and conventional It can be suitably manufactured according to the phosphorus method. Examples of foods to which the health extract of the present invention can be added include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, various soups, beverages, It may be in any one form selected from tea, drink, alcoholic beverage, and vitamin complex, and includes all health functional foods in the usual sense.
본 발명의 건강기능식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 및 천연 풍미제, 착색제 및 증진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 본 발명의 건강기능식품 조성물은 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다.The health functional food composition of the present invention includes various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective properties. It may contain colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like. In addition, it may contain pulp for the manufacture of natural fruit juices and vegetable beverages. These components may be used independently or in combination. The health functional food composition of the present invention may contain various flavoring agents or natural carbohydrates as additional ingredients. The natural carbohydrates are monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As the sweetener, natural sweeteners such as taumatin and stevia extract, and synthetic sweeteners such as saccharin and aspartame can be used.
또한, 본 발명은 건강 추출물을 유효성분으로 포함하는 독감 백신 접종에 의해 형성되는 중화항체 생성율 증진용 약학 조성물에 관한 것이다.In addition, the present invention relates to a pharmaceutical composition for enhancing the production rate of neutralizing antibodies formed by flu vaccination comprising a health extract as an active ingredient.
본 발명의 약학 조성물은 상기 건강 추출물 이외에 추가로 담체, 부형제 또는 희석제를 더 포함할 수 있고, 본 발명의 약학 조성물은 경구 또는 비경구로 투여될 수 있으며, 비 경구 투여 시 피부 외용 또는 복강 내, 직장, 정맥, 근육, 피하, 자궁 내 경막 또는 뇌혈관 내 주사 방식을 선택하는 것이 바람직하다.The pharmaceutical composition of the present invention may further include a carrier, excipient, or diluent in addition to the health extract, and the pharmaceutical composition of the present invention may be administered orally or parenterally. When administered parenterally, the pharmaceutical composition may be administered externally to the skin or intraperitoneally, or , It is preferable to select intravenous, intramuscular, subcutaneous, intrauterine dura mater or cerebrovascular injection.
본 발명의 약학 조성물은 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형 제제는 하나 이상의 화합물에 적어도 하나 이상의 부형제 예를 들면, 전분, 탄산칼슘, 수크로오스(sucrose) 또는 락토오스(lactose), 젤라틴 등을 섞어 조제된다. 또한, 단순한 부형제 이외에 스테아린산 마그네슘, 탈크 등과 같은 윤활제들도 사용된다. 경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성 용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성 용제 및 현탁 용제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈tween) 61, 카카오지, 라우린지, 글리세로 젤라틴 등이 사용될 수 있다.The pharmaceutical composition of the present invention may be prepared using diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrants, and surfactants. Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and such solid preparations include at least one excipient in one or more compounds, such as starch, calcium carbonate, sucrose, or lactose ( lactose), gelatin, etc. In addition, in addition to simple excipients, lubricants such as magnesium stearate and talc are also used. Liquid preparations for oral administration include suspensions, liquid solutions, emulsions, syrups, etc.In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweetening agents, fragrances, and preservatives may be included. have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin, glycero gelatin, and the like may be used.
본 발명에 따른 조성물은 약제학적으로 유효한 양으로 투여한다. 본 발명에 있어서, '약제학적으로 유효한 양'은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효용량 수준은 환자의 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 조성물은 개별 치료제로 투여하거나 다른 치료제와 병용하여 투여될 수 있고 종래의 치료제와는 순차적 또는 동시에 투여될 수 있으며, 단일 또는 다중 투여될 수 있다. 상기한 요소들을 모두 고려하여 부작용없이 최소한의 양으로 최대 효과를 얻을 수 있는 양을 투여하는 것이 중요하며, 이는 당업자에 의해 용이하게 결정될 수 있다.The composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, the'pharmaceutically effective amount' means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the effective dose level is the type of disease, severity, and drug activity of the patient. , Sensitivity to drugs, time of administration, route of administration and rate of excretion, duration of treatment, factors including drugs used concurrently, and other factors well known in the medical field. The composition of the present invention may be administered as an individual therapeutic agent or administered in combination with other therapeutic agents, may be administered sequentially or simultaneously with a conventional therapeutic agent, and may be administered single or multiple. It is important to administer an amount capable of obtaining the maximum effect in a minimum amount without side effects in consideration of all the above factors, and this can be easily determined by a person skilled in the art.
본 발명의 조성물의 투여량은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설률 및 질환의 중증도에 따라 그 범위가 다양하게 사용할 수 있다.The dosage of the composition of the present invention can be used in various ranges according to the patient's weight, age, sex, health status, diet, administration time, administration method, excretion rate, and severity of disease.
또한, 본 발명은 건강 추출물을 유효성분으로 포함하는 중화항체 생성율 증진용 독감 백신 보조제에 관한 것이다.In addition, the present invention relates to a flu vaccine adjuvant for enhancing the production rate of neutralizing antibodies comprising a health extract as an active ingredient.
상기 독감 백신 보조제는 건강 추출물에 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상을 함유할 수 있다. 상기 독감 백신 보조제는 임상 투여 시에 경구 또는 비경구로 투여가 가능하며, 비경구 투여 시 복강 내 주사, 직장 내 주사, 피하주사, 정맥주사, 근육 내 주사, 자궁 내 경막주사, 뇌혈관 내 주사 또는 흉부 내 주사에 의해 투여될 수 있고, 일반적인 의약품 제제의 형태로 사용될 수 있다. The flu vaccine adjuvant may contain one or more active ingredients exhibiting the same or similar function in addition to the health extract. The flu vaccine adjuvant can be administered orally or parenterally during clinical administration, and when administered parenterally, intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, intrauterine dural injection, cerebrovascular injection or It can be administered by intrathoracic injection, and can be used in the form of a general pharmaceutical formulation.
본 발명의 독감 백신 보조제는 실제 임상 투여 시에 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제된다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌글리콜(Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.The flu vaccine adjuvant of the present invention can be administered in various parenteral formulations at the time of actual clinical administration, but when formulated, diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants are used. It is prepared by doing. Preparations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, and suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, and injectable ester such as ethyl oleate may be used. As a base for suppositories, witepsol, macrogol, tween 61, cacao butter, laurin, glycerogelatin, and the like may be used.
이하, 실시예를 이용하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로 본 발명의 범위가 이들에 의해 제한되지 않는다는 것은 당해 기술분야에서 통상의 지식을 가진 자에게 있어 자명한 것이다. Hereinafter, the present invention will be described in more detail using examples. These examples are only for describing the present invention in more detail, and it is apparent to those of ordinary skill in the art that the scope of the present invention is not limited thereto.
실시예 1. 건강 추출물의 제조Example 1. Preparation of healthy extract
건강 무게 대비 10배의 70%(v/v) 에탄올을 첨가하여 82±2℃에서 3시간 동안 환류 추출을 하였다. 그 후 거름망 필터 후, 솜 필터를 진행하였다. 필터된 용액은 동결건조하여 분말화하였다.Reflux extraction was performed at 82±2° C. for 3 hours by adding 70% (v/v) ethanol 10 times the healthy weight. Then, after the sieve filter, the cotton filter was performed. The filtered solution was lyophilized to powder.
[동물모델 및 재료][Animal model and materials]
본 발명의 실험동물은 Balb/c 8주령 암컷 마우스를 오리엔트 바이오로부터 구입하였으며, 상기 시클로포스파미드(cyclophosphamide, Sigma) 150mg/kg을 2일 간격으로 총 3회 복강 내 주사하였다. 실험군은 마지막 항암제 투여 후, 3일째부터 10일 동안 500mg/kg의 건강추출물을 경구투여하였고, 대조군은 증류수를 경구투여하였다. 경구투여 10일 종료 후, 1일째에 마우스 당 각 인플루엔자 항체 1㎍의 독감 백신을 근육 내 주사하였다. 백신 접종 후 4주째에 부검을 통해서 혈청 및 비장세포를 분리하였다.In the experimental animal of the present invention, a Balb/c 8-week-old female mouse was purchased from Orient Bio, and the cyclophosphamide (Sigma) 150mg/kg was injected intraperitoneally three times at intervals of 2 days. The experimental group was orally administered 500mg/kg of healthy extract for 10 days from the 3rd day after the last anticancer drug administration, and the control group was orally administered distilled water. After the end of the oral administration on the 10th day, on the 1st day, a flu vaccine of 1 µg of each influenza antibody was injected intramuscularly. At 4 weeks after vaccination, serum and splenocytes were isolated through autopsy.
상기 백신은 2017-2018 seasonal vaccine으로, A/Michigan/45/2015(H1N1), A/Hong Kong/4801/2014(H3N2), B/Phuket/3073/2013, B/Brisbane/60/2008을 포함하는 것이다.The vaccine is a 2017-2018 seasonal vaccine, including A/Michigan/45/2015(H1N1), A/Hong Kong/4801/2014(H3N2), B/Phuket/3073/2013, B/Brisbane/60/2008 Is to do.
실시예 2. ELISA를 이용한 항원 특이 항체 형성 여부 확인Example 2. Confirmation of antigen-specific antibody formation using ELISA
4가 백신 용액을 이용하여, 각각의 인플루엔자 항원이 1㎍/㎖씩 로딩되도록 되도록 웰당 총 4㎍/㎖의 항원을 96웰 플레이트에 코팅하고 블로킹한 후, 마우스 혈청을 10,000배 희석해서 인큐베이션 하고, HRP가 붙어있는 anti-IgG 항체, anti-IgG1 항체, anti-IgG2a 항체(각각은 1,000배 희석)를 이용해서 인플루엔자 항원 특이 항체 titer를 효소결합면역흡착검사법(ELISA)으로 측정하였다.Using a tetravalent vaccine solution, a total of 4 μg/ml of antigen per well was coated on a 96-well plate and blocked so that each influenza antigen was loaded at 1 μg/ml, and then, the mouse serum was diluted 10,000 times and incubated. Anti-IgG antibody with HRP, anti-IgG1 antibody, and anti-IgG2a antibody (each diluted 1,000 times) was used to measure the titer of the influenza antigen-specific antibody by enzyme-linked immunosorbent assay (ELISA).
그 결과 도 1에 개시한 바와 같이, 건강 추출물을 투여하지 않은 항암제 투여군에 비해 건강 추출물을 투여한 군에서의 IgG 및 IgG1의 생성이 증진된 것을 확인하였다.As a result, as disclosed in FIG. 1, it was confirmed that the production of IgG and IgG1 in the group administered with the healthy extract was improved compared to the group administered with the anticancer agent not administered with the healthy extract.
실시예 3. Example 3. in vitroin vitro 항원 자극에 대한 사이토카인 생성 Cytokine production against antigen stimulation
(1) IFN-γ 및 IL-4의 함량 변화 확인(1) Confirmation of changes in the content of IFN-γ and IL-4
각각의 개체마다 비장세포를 분리한 후, 각각의 웰에 anti-mouse CD28 Ab(1㎍/㎖, biolegend) 자극 군과 anti-mouse CD28 Ab+인플루엔자 항원(0.5㎍/㎖) 자극 군으로 나누어 자극을 주고, 배양해서 2일 후에 배양액의 상등액을 분리하였다. 배양액에서 각각의 사이토카인의 생성 값을 구하였다. 구체적으로 T H1 반응 평가를 위한 사이토카인 IFN-γ 및 T H2 반응 평가를 위한 사이토카인 IL-4의 함량 변화를 확인하였다. After separating splenocytes for each individual, stimulation was divided into an anti-mouse CD28 Ab (1㎍/㎖, biolegend) stimulation group and an anti-mouse CD28 Ab + influenza antigen (0.5㎍/mL) stimulation group in each well. Then, after 2 days of culture, the supernatant of the culture solution was separated. The production values of each cytokine were determined in the culture medium. Specifically, changes in the content of the cytokine IFN-γ for T H 1 reaction evaluation and the cytokine IL-4 for T H 2 reaction evaluation were confirmed.
그 결과 도 2에 개시한 바와 같이 IFN-γ은 항암제 투여군 및 항암제 투여 후 건강추출물을 투여한 군에서 모두 감소한 것을 확인하였고, IL-4의 함량 변화는 항암제만 투여한 군에서는 오히려 아무것도 투여하지 않은 대조군에 비해 IL-4의 함량이 증가하였으며, 항암제 투여 후, 본 발명의 건강추출물을 투여한 군에서는 아무것도 투여하지 않은 대조군에 비해 감소하였다. As a result, as disclosed in FIG. 2, it was confirmed that IFN-γ decreased both in the group administered with the anticancer agent and the group administered with the health extract after the administration of the anticancer agent, and the change in the content of IL-4 was rather nothing in the group administered with only the anticancer agent. The content of IL-4 was increased compared to the control group, and after administration of the anticancer agent, the group administered the health extract of the present invention decreased compared to the control group to which nothing was administered.
(2) IFN-γ/ IL-4의 비율 확인(2) Check the ratio of IFN-γ/IL-4
상기 IFN-γ 및 IL-4의 함량의 변화를 확인한 후, 이들의 함량비를 분석하였다. After confirming the change in the content of IFN-γ and IL-4, the content ratio thereof was analyzed.
그 결과, 도 3에 개시한 바와 같이 항암제만 투여했을 때 감소했던 IFN-γ/ IL-4의 비율이 항암제 및 건강 추출물을 투여한 군에서 증진된 것을 확인하였다. As a result, it was confirmed that the ratio of IFN-γ/IL-4 decreased when only the anticancer agent was administered as disclosed in FIG. 3 was improved in the group to which the anticancer agent and health extract were administered.
이후, 도 4에 개시한 바와 같이, IFN-γ/IL-4의 비율과 IgG 생성량과의 관계를 확인한 결과, 정비례관계가 있다는 것을 확인하였다.Thereafter, as disclosed in FIG. 4, as a result of confirming the relationship between the ratio of IFN-γ/IL-4 and the amount of IgG produced, it was confirmed that there was a direct proportional relationship.
실시예 4. 적혈구 응집억제 검사를 이용한 중화항체 생성율 측정Example 4. Measurement of neutralizing antibody production rate using erythrocyte aggregation inhibition test
백신을 접종하고 30일이 경과한 후, 적혈구 응집 억제 검사를 실시하였다. After 30 days of vaccination had elapsed, a hemagglutination inhibition test was performed.
그 결과, 표 1 및 2에 개시한 바와 같이, 항암제만 투여한 군에 비해 항암제 투여 후 본 발명의 건강 추출물을 투여한 군의 중화항체(항체가 40 이상의 항체) 생성율이 증진된 것을 확인하였다.As a result, as disclosed in Tables 1 and 2, it was confirmed that the production rate of neutralizing antibodies (antibodies having an antibody of 40 or more) was increased in the group administered the health extract of the present invention after the administration of the anticancer agent compared to the group administered only the anticancer agent.
건강 추출물을 투여한 군의 H1N1에 대한 중화항체(항체가 40 이상의 항체) 생성율 The production rate of neutralizing antibodies (antibodies of 40 or more) against H1N1 in the group administered with healthy extract
H1N1H1N1 혈청방어(seroprotection); 적혈구 응집 억제 titer≥40Serum protection; Hemagglutination inhibition titer≥40 중화항체 생성율(%)Neutralizing antibody production rate (%)
40 이상40 or more 40 미만Less than 40
항암제 단독투여Anticancer drug alone 22 66 25.025.0
항암제 투여 후, 건강 추출물 투여After administration of anticancer drug, administration of health extract 66 22 75.075.0
건강 추출물을 투여한 군의 H3N2에 대한 중화항체(항체가 40 이상의 항체) 생성율 Production rate of neutralizing antibodies (antibodies of 40 or more) against H3N2 in the group administered with healthy extract
H3N2H3N2 혈청방어(seroprotection); 적혈구 응집 억제 titer≥40Serum protection; Hemagglutination inhibition titer≥40 중화항체 생성율(%)Neutralizing antibody production rate (%)
40 이상40 or more 40 미만Less than 40
항암제 단독투여Anticancer drug alone 1One 77 12.512.5
항암제 투여 후, 건강 추출물 투여After administration of anticancer drug, administration of health extract 22 66 25.025.0

Claims (6)

  1. 건강 추출물을 유효성분으로 포함하는 독감 백신 접종에 의해 형성되는 중화항체 생성율 증진용 건강기능식품 조성물.Health functional food composition for enhancing the production rate of neutralizing antibodies formed by flu vaccination comprising a health extract as an active ingredient.
  2. 제1항에 있어서, 상기 건강 추출물의 추출 용매는 물, C 1~C 4의 저급 알코올 또는 이들의 혼합물인 것을 특징으로 하는 독감 백신 접종에 의해 형성되는 중화항체 생성율 증진용 건강기능식품 조성물.The health functional food composition of claim 1, wherein the extraction solvent of the health extract is water, a lower alcohol of C 1 to C 4 or a mixture thereof.
  3. 제1항에 있어서, 상기 중화항체는 H1N1 또는 H3N2의 A형 독감바이러스 감염에 대한 항체 또는 B/Phuket 또는 B/Bristone의 B형 독감바이러스 감염에 대한 항체인 것을 특징으로 하는 독감 백신 접종에 의해 형성되는 중화항체 생성율 증진용 건강기능식품 조성물.The method of claim 1, wherein the neutralizing antibody is an antibody against H1N1 or H3N2 type A influenza virus infection, or B/Phuket or B/Bristone against type B influenza virus infection. Health functional food composition for enhancing the production rate of neutralizing antibodies.
  4. 제1항에 있어서, 상기 조성물은 면역력이 저하된 암환자 또는 60세 이상의 노인에게 독감 백신 접종 전에 투여하기 위한 것임을 특징으로 하는 중화항체 생성율 증진용 건강기능식품 조성물.According to claim 1, The composition is a health functional food composition for enhancing the production rate of neutralizing antibodies, characterized in that for administering to a cancer patient with reduced immunity or an elderly person aged 60 years or older before the inoculation of the flu vaccine.
  5. 건강 추출물을 유효성분으로 포함하는 독감 백신 접종에 의해 형성되는 중화항체 생성율 증진용 약학 조성물.A pharmaceutical composition for enhancing the production rate of neutralizing antibodies formed by flu vaccination comprising a health extract as an active ingredient.
  6. 건강 추출물을 유효성분으로 포함하는 중화항체 생성율 증진용 독감 백신 보조제.Influenza vaccine adjuvant for enhancing the production rate of neutralizing antibodies containing healthy extracts as an active ingredient.
PCT/KR2020/004542 2019-04-04 2020-04-03 Composition containing healthy extract as active ingredient for enhancing production rates of neutralizing antibodies WO2020204644A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2019-0039630 2019-04-04
KR1020190039630A KR102224051B1 (en) 2019-04-04 2019-04-04 Composition for enhancing neutralizing antibody generation rate comprising Zingiber officinale extract as effective component

Publications (1)

Publication Number Publication Date
WO2020204644A1 true WO2020204644A1 (en) 2020-10-08

Family

ID=72667211

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2020/004542 WO2020204644A1 (en) 2019-04-04 2020-04-03 Composition containing healthy extract as active ingredient for enhancing production rates of neutralizing antibodies

Country Status (2)

Country Link
KR (1) KR102224051B1 (en)
WO (1) WO2020204644A1 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070102487A (en) * 2004-12-14 2007-10-18 더 퀴글리 코포레이션 Compositions and methods for reducing the transmissivity of illnesses
KR20110049618A (en) * 2009-11-05 2011-05-12 한국 한의학 연구원 Composition for prevention or treatment of disease originated from influenza virus
KR20120100264A (en) * 2011-03-03 2012-09-12 건국대학교 산학협력단 A novel compound isolated from kaempferia pandurata rox and use of the same as antiviral agent
KR101413528B1 (en) * 2011-02-23 2014-07-02 울산대학교 산학협력단 Composition comprising ６―gingerol having immune enhancement activity
KR20180030970A (en) * 2015-06-10 2018-03-27 라만 메타 Formulation for treatment of mouth, throat and respiratory tract diseases

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070102487A (en) * 2004-12-14 2007-10-18 더 퀴글리 코포레이션 Compositions and methods for reducing the transmissivity of illnesses
KR20110049618A (en) * 2009-11-05 2011-05-12 한국 한의학 연구원 Composition for prevention or treatment of disease originated from influenza virus
KR101413528B1 (en) * 2011-02-23 2014-07-02 울산대학교 산학협력단 Composition comprising ６―gingerol having immune enhancement activity
KR20120100264A (en) * 2011-03-03 2012-09-12 건국대학교 산학협력단 A novel compound isolated from kaempferia pandurata rox and use of the same as antiviral agent
KR20180030970A (en) * 2015-06-10 2018-03-27 라만 메타 Formulation for treatment of mouth, throat and respiratory tract diseases

Also Published As

Publication number Publication date
KR102224051B1 (en) 2021-03-09
KR20200117477A (en) 2020-10-14

Similar Documents

Publication Publication Date Title
CN114502184A (en) Pharmaceutical and food compositions for the prevention and treatment of coronavirus infection comprising Elaeagnus dulcis extract
WO2019124863A1 (en) Composition containing schisandra chinensis leaf extract as active ingredient for prevention, improvement and treatment of atopic dermatitis
EP3443972A1 (en) Pharmaceutical composition for preventing or treating respiratory disease comprising extract of justicia procumbens l.
JPWO2006137122A1 (en) Anti-AIDS agent
KR20170121866A (en) Extract of cordyceps militaris, manufacturing method of the same, and composition comprising cordycepin isolated thereform for the prevent or treatment of lung cancer
US20130041023A1 (en) Composition for Preventing or Treating Rotavirus Infection Comprising Licorice Extract
WO2020204644A1 (en) Composition containing healthy extract as active ingredient for enhancing production rates of neutralizing antibodies
WO2022124803A1 (en) Composition for preventing, alleviating, or treating allergic diseases, comprising extract of spatholobus suberectus as active ingredient
WO2009151173A1 (en) Pharmaceutical compositions for prevention and treatment of viral diseases containing rhodiola extracts, fractions, the isolated flavonoid compounds therefrom, derivatives compounds thereof or the pharmaceutically acceptable salts as an active ingredient
WO2014133286A1 (en) Composition containing extracts of artemisia iwayomogi and curcuma longa as active ingredients for preventing, inhibiting, or treating obesity-related diseases
KR100999872B1 (en) Pharmaceutical compositions for prevention and treatment of viral diseases containing rodiola extracts, fractions, the isolated flavonoid compounds therefrom, derivatives compounds thereof or the pharmaceutically acceptable salts as an active ingredient
KR100825070B1 (en) Pharmaceutical composition for the prevention and treatment of atopy and contact dermatitis, containing mixture extract of phellinus linteus hypha and gastrodia elata
KR20110049722A (en) A composition for anti-virus comprising the extract or fraction of aleurites fordii as an effective ingredient
KR101115063B1 (en) Composition for prevention and treatment of influenza virus and composition for inhibiting the activity of neuraminidase
WO2018056772A1 (en) Antitumor composition or antitumor immunity-inducing composition comprising erysimum sp. extract as effective ingredient
KR100531633B1 (en) Composition comprising the extract of Korean Phellinus linteus for the treatment and protection of cold or flu
KR20150086928A (en) Composition for prevention or treatment of influenza virus infection comprising curcuminoid and licorice extracts or fraction thereof
KR102542854B1 (en) Functional food composition for suppressing of irritable bowel syndrome
EP4151226A1 (en) Coronavirus therapeutic agent comprising zanthoxylum piperitum leaf extract as active ingredient
KR102671544B1 (en) Composition for relieving stress and enhancing immune comprising medicinal herb complex extract as effective component
KR102226992B1 (en) Compositions for inhibiting the activity of neuraminidase comprising diarylheptanoids from Alpinia officinarum
KR20160143628A (en) Composition for prevention or treatment of influenza virus infection comprising curcuminoid and licorice extracts or fraction thereof
KR101705760B1 (en) Composition for composition for prevention or treatment of rotavirus infection comprising ecklonia cava
KR101946925B1 (en) Composition for enhancing immunity, prventing or treating neurodegenerative disease using goji berry, mulberry and jujube
KR20220161908A (en) Composition for improving immunity or for antiviral

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20784240

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 20784240

Country of ref document: EP

Kind code of ref document: A1